Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer
Sundee Dees, Rajkumar Ganesan, Sanjaya Singh, et al.
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 12, pp. 2409-2421
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Feng Ye, Saikat Dewanjee, Yuehua Li, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 279
Immunotherapy in breast cancer: an overview of current strategies and perspectives
Véronique Debien, Alex De Caluwé, Xiaoxiao Wang, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 200
Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment
Joshua Li, Julia Y. Tsang, Gary M. Tse
Cancers (2021) Vol. 13, Iss. 16, pp. 4233-4233
Open Access | Times Cited: 130
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
Chenyi Luo, Peipei Wang, Siqi He, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 103
CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application
Yu-Huan Yang, Jiawei Liu, Lü Chen, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 6, pp. 2609-2626
Open Access | Times Cited: 84
Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance
Taniya Saha, Kiven Erique Lukong
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 81
A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer
Hitesh Kumar, Neha Gupta, Rupshee Jain, et al.
Journal of Advanced Research (2023) Vol. 54, pp. 271-292
Open Access | Times Cited: 60
Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer
Moumita Kundu, Ramesh Butti, Venketesh K. Panda, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 50
Therapeutic potential of CAR T cell in malignancies: A scoping review
Ali Zarezadeh Mehrabadi, Reza Ranjbar, Mahdieh Farzanehpour, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112512-112512
Open Access | Times Cited: 89
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress
Chiara Corti, Konstantinos Venetis, Elham Sajjadi, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 6, pp. 593-605
Open Access | Times Cited: 54
Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
Sunny Kumar, Mouli Chatterjee, Pratyasha Ghosh, et al.
Genes & Diseases (2022) Vol. 10, Iss. 4, pp. 1318-1350
Open Access | Times Cited: 54
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Congqi Shi, Kaiyu Qin, Anqi Lin, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 43
Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches
Veerle Geurts, Marleen Kok
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 6, pp. 628-643
Open Access | Times Cited: 40
Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review
Boya Lu, Elango Natarajan, Hanumantha Rao Balaji Raghavendran, et al.
Technology in Cancer Research & Treatment (2023) Vol. 22
Open Access | Times Cited: 39
CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
Lusine Hovhannisyan, Carsten Riether, Daniel M. Aebersold, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 35
Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
Kyu Sic You, Yong Weon Yi, Jeonghee Cho, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 6, pp. 589-589
Open Access | Times Cited: 49
Clinical trials of immunotherapy in triple-negative breast cancer
Frederick M. Howard, Alexander T. Pearson, Rita Nanda
Breast Cancer Research and Treatment (2022) Vol. 195, Iss. 1, pp. 1-15
Open Access | Times Cited: 38
Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
Rita Ribeiro, Maria João Carvalho, João Gonçalves, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 36
Prospects of Immunotherapy for Triple-Negative Breast Cancer
Dan Qiu, Guijuan Zhang, Xianxin Yan, et al.
Frontiers in Oncology (2022) Vol. 11
Open Access | Times Cited: 31
Applications of Extracellular Vesicles in Triple-Negative Breast Cancer
Frédéric St-Denis Bissonnette, Rachil Khoury, Karan Mediratta, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 451-451
Open Access | Times Cited: 26
Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer
Mónica Cejuela Solís, Andrea Vethencourt, Sònia Pernas
Current Oncology Reports (2022) Vol. 24, Iss. 12, pp. 1801-1819
Closed Access | Times Cited: 25
New Achievements for the Treatment of Triple-Negative Breast Cancer
Alessia Catalano, Domenico Iacopetta, Jessica Ceramella, et al.
Applied Sciences (2022) Vol. 12, Iss. 11, pp. 5554-5554
Open Access | Times Cited: 24
Trends and Technology Development in Life Science
С. Прохоров Е
(2023)
Open Access | Times Cited: 15
Immunotherapy: breakthrough in Cancer Treatment
Reshmi Gopalakrishnan, B Thamaraiselvi
(2023), pp. 171-177
Open Access | Times Cited: 15
Genetically Modified Organisms (GMOs): Balancing Benefits and Ethical Considerations
Deepa VH, Prakriti Pushp
(2023), pp. 178-190
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top